Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMPNASDAQ:MLYSNASDAQ:NAGENYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPImmutep$1.74+0.6%$1.78$1.32▼$2.80$254.11M1.76209,018 shs46,848 shsMLYSMineralys Therapeutics$14.32-4.0%$14.74$8.24▼$18.38$933.31M-0.17510,238 shs589,118 shsNAGENiagen Bioscience$13.63-3.6%$9.25$2.31▼$14.49$1.07B2.08858,693 shs879,867 shsRCUSArcus Biosciences$9.25-1.1%$8.64$6.50▼$18.98$979.44M0.83879,024 shs781,402 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPImmutep+0.58%-6.45%-4.92%-2.25%-32.03%MLYSMineralys Therapeutics-4.02%-11.17%-5.23%+0.49%+13.65%NAGENiagen Bioscience-3.61%+5.25%+34.95%+73.85%+325.94%RCUSArcus Biosciences-1.28%-7.45%+8.06%-1.02%-41.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMPImmutep1.3391 of 5 stars3.51.00.00.02.60.00.0MLYSMineralys Therapeutics2.7423 of 5 stars3.43.00.00.02.04.20.0NAGENiagen Bioscience1.4492 of 5 stars3.50.00.00.02.60.00.0RCUSArcus Biosciences2.2665 of 5 stars4.50.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPImmutep 3.00Buy$7.00302.30% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25125.21% UpsideNAGENiagen Bioscience 3.00Buy$19.5043.07% UpsideRCUSArcus Biosciences 2.90Moderate Buy$24.13160.81% UpsideCurrent Analyst Ratings BreakdownLatest IMMP, NAGE, MLYS, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.006/10/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.006/6/2025NAGENiagen BioscienceRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $23.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.005/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.004/23/2025RCUSArcus BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $14.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPImmutep$5.14M49.44N/AN/A$1.05 per share1.66MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANAGENiagen Bioscience$107.93M9.95N/AN/AN/A∞RCUSArcus Biosciences$141M6.95N/AN/A$6.17 per share1.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)NAGENiagen BioscienceN/A$0.1780.18∞N/AN/AN/AN/AN/ARCUSArcus Biosciences-$307M-$4.19N/AN/AN/A-102.66%-45.59%-22.38%8/4/2025 (Estimated)Latest IMMP, NAGE, MLYS, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPImmutepN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPImmutep0.0118.2518.25MLYSMineralys TherapeuticsN/A14.0214.02NAGENiagen BioscienceN/AN/AN/ARCUSArcus Biosciences0.085.245.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPImmutep2.32%MLYSMineralys Therapeutics84.46%NAGENiagen Bioscience15.41%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipIMMPImmutep3.07%MLYSMineralys Therapeutics25.56%NAGENiagen Bioscience9.39%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPImmutep2,021146.04 million141.09 millionOptionableMLYSMineralys Therapeutics2865.18 million33.27 millionOptionableNAGENiagen Bioscience12078.77 millionN/AN/ARCUSArcus Biosciences500105.89 million80.26 millionOptionableIMMP, NAGE, MLYS, and RCUS HeadlinesRecent News About These CompaniesThe trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gambleJune 13 at 12:56 PM | fiercebiotech.comArcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?June 11 at 3:18 PM | marketbeat.comStock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)June 11 at 12:56 PM | marketbeat.comCantor Fitzgerald Comments on RCUS FY2026 EarningsJune 11 at 2:35 AM | americanbankingnews.comArcus Biosciences Announces New Employment Inducement GrantsJune 10, 2025 | businesswire.comResearch Analysts Offer Predictions for RCUS FY2026 EarningsJune 10, 2025 | marketbeat.comH.C. Wainwright maintains Buy rating for Arcus Biosciences stockJune 4, 2025 | investing.comArcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in MayJune 4, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What HappenedJune 4, 2025 | marketbeat.comNuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)June 4, 2025 | marketbeat.comArcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s WeliregJune 2, 2025 | biospace.comArcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s WeliregJune 2, 2025 | thepharmaletter.comInitial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of ...June 1, 2025 | gurufocus.comInitial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed ResponseJune 1, 2025 | businesswire.comArcus Biosciences (NYSE:RCUS) Stock Price Down 8.6% - Time to Sell?May 31, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 30, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsMay 27, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Millennium Management LLCMay 25, 2025 | marketbeat.comArcus Biosciences describes new c-Kit inhibitorsMay 24, 2025 | bioworld.comWoodline Partners LP Purchases 45,497 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 22, 2025 | marketbeat.comSuvretta Capital Management LLC Has $8.58 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioThese 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1By Leo Miller | May 22, 2025View These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernLowe’s Stock Uptrend Can Continue for These 2 ReasonsBy Thomas Hughes | May 21, 2025View Lowe’s Stock Uptrend Can Continue for These 2 ReasonsIMMP, NAGE, MLYS, and RCUS Company DescriptionsImmutep NASDAQ:IMMP$1.74 +0.01 (+0.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.76 +0.02 (+1.15%) As of 06/13/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Mineralys Therapeutics NASDAQ:MLYS$14.32 -0.60 (-4.02%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$14.56 +0.23 (+1.64%) As of 06/13/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Niagen Bioscience NASDAQ:NAGE$13.63 -0.51 (-3.61%) As of 06/13/2025 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Arcus Biosciences NYSE:RCUS$9.25 -0.10 (-1.07%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$9.24 -0.01 (-0.05%) As of 06/13/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
